Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash & Equivalents (2019 - 2025)

Lyell Immunopharma's Cash & Equivalents history spans 7 years, with the latest figure at $98.8 million for Q2 2025.

  • For Q2 2025, Cash & Equivalents fell 25.95% year-over-year to $98.8 million; the TTM value through Jun 2025 reached $98.8 million, down 25.95%, while the annual FY2024 figure was $105.6 million, 27.5% down from the prior year.
  • Cash & Equivalents for Q2 2025 was $98.8 million at Lyell Immunopharma, down from $105.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $564.4 million in Q2 2021 and bottomed at $98.8 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $145.6 million (2023), against an average of $205.5 million.
  • The largest annual shift saw Cash & Equivalents soared 191.75% in 2021 before it plummeted 70.44% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $293.8 million in 2021, then crashed by 57.95% to $123.6 million in 2022, then increased by 17.88% to $145.6 million in 2023, then fell by 27.5% to $105.6 million in 2024, then fell by 6.43% to $98.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Cash & Equivalents are $98.8 million (Q2 2025), $105.6 million (Q4 2024), and $100.3 million (Q3 2024).